Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Scheinberg joins Galena's SAB

This article was originally published in Scrip

Executive Summary

Galena Biopharma, a biotech company developing targeted oncology treatments, has appointed Dr David Scheinberg to its scientific advisory board. Dr Scheinberg is Memorial Sloan-Kettering Cancer Center's Vincent Astor chair, chair of the Molecular Pharmacology and Chemistry Program in the Sloan-Kettering Institute, and chair of the Experimental Therapeutics and the Nanotechnology Centers at Memorial Sloan-Kettering. In addition, Dr Scheinberg is professor of medicine and pharmacology at Weill-Cornell Medical College and serves on the boards of Progenics and Contrafect, and the scientific advisory boards of Actinium Pharmaceuticals, Ensysce Biosciences and OncoPep.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016485

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel